Research Article
Design and In Silico and In Vitro Evaluations of a Novel Nicotinamide Derivative as a VEGFR-2 Inhibitor
Figure 11
Optimized chemical structure (a) and the Mulliken charge (b) of the targeted nicotinamide derivative at the B3LYB/6-311G++(d,p) level.
| (a) |
| (b) |